Form 6-K NOVARTIS AG For: Oct 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Novartis Q3 preview: BofA sees strong product momentum, potential EBIT Upgrade
October 27, 2025 4:00 PM EDTNovartis (NYSE: NVS) is set to report third-quarter results that Bank of America expects will be broadly in line with consensus, underpinned by strong prescription trends for key growth drivers.
According to BofA analyst Sachin Jain, the Neutral-rated drugmakers Q3 earnings per share are forecast at $2.30, up 12% year-on-year, on sales of about $14... More
